Potassium-Competitive Acid Blockers: New Opportunities of Antisecretory Therapy in Gastroesophageal Reflux Disease
Abstract
Aim: to present modern data on the efficacy and safety of using potassium-competitive acid blockers (P-CAB) using tegoprazan as an example in patients with gastroesophageal reflux disease. Key points. Potassium-competitive blockers of hydrochloric acid secretion, according to clinical studies, have demonstrated high clinical efficacy and safety in patients with gastroesophageal reflux disease. The advantages of this class of drugs include a faster and longer-lasting antisecretory effect, which does not depend on food intake, as well as the absence of the influence of genetic polymorphisms of the CYP2C19 isoenzyme on pharmacokinetics and the risk of drug interactions. In patients with nocturnal heartburn, the potassium-competitive acid blocker tegoprazan may be the drug of choice to achieve a faster and longer-lasting clinical effect and improve sleep quality. Tegoprazan is effective against nocturnal acid breakthroughs. In several studies, tegoprazan was superior to placebo and proton pump inhibitors (PPIs) in eliminating major symptoms in patients with nonerosive reflux disease and to PPIs in treating erosive esophagitis. P-CABs are considered the drugs of choice in the treatment of gastroesophageal reflux disease refractory to PPIs. Conclusion. Further studies are needed, including in the Russian Federation, to confirm the high efficacy and safety of tegoprazan.
Read the paper
Related studies
- Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
- Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
- Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study
- Ethnic and socioeconomic differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.